Hello Part-time Trader…👋

Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:

• Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.

• Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.

• Top Pre-Market Movers: Identify early winners poised for a strong market opening.

• Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.

• FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.

Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.

Happening Today

✓ 08:30 AM ET – Average Hourly Earnings (MoM) (Mar)

✓ 08:30 AM ET – Nonfarm Payrolls (Mar)

✓ 08:30 AM ET – Unemployment Rate (Mar)

✓ 08:30 PM ET – Average Hourly Earnings (YoY) (YoY) (Mar)

PREMARKET SNAPSHOT 📈

Stock futures are down across the board, with the NASDAQ leading the decline at -1.55%.

SECTOR SNAPSHOT ✨

Looking at sector performance, Information Technology stands out with a significant 1.72% decline.

Unusual Volume

📈 WiSA Technologies Inc (WISA) declined -3.29% to $0.02 on a whopping 170.43 million shares traded.

📈 Investors went wild, sending Candel Therapeutics Inc (CADL) stock soaring 280.95% to $6.40 on a massive volume of 143.93 million shares after the company revealed encouraging interim results from a randomized Phase 2 clinical trial of CAN-2409 in Non-Metastatic Pancreatic Cancer.

📈 Abnormal activity shook TC BioPharm (Holdings) plc ADR (TCBP), pushing it up 50.00% to $1.95 on a whopping 87.76 million shares traded after announcing execution of non-binding letter of intent for acquisition of NK Platform Technologies.

📈 Aurora Cannabis Inc (ACB) stock recently closed -2.08% lower at $7.06 on substantial volume of 63.41 million shares.

📈 SINTX Technologies Inc (SINT) increase by 9.13% in a single trading session, with abnormally high trading volume of 60.47 million shares. The company recently declared pricing of $1.5 million public offering of common stock.

Premarket Movers

22nd Century Group, Inc. (XXII) sees a significant 16.89% increase, reaching a pre-market price of $1.73 after reporting that it has signed a significant new contract manufacturing agreement for the production of branded conventional cigarette products.

HUB Cyber Security Ltd. (HUBC) demonstrates a noteworthy 50.00% surge, with a pre-market price of $1.56. The company announced a successful $8 million financing acquisition via a straight debt arrangement.

Important FDA 

Recently Announced

Regeneron Pharmaceuticals (REGN) recently encountered setbacks as the FDA issued Complete Response Letters (CRLs) for their drug odronextamab's Biologics License Application (BLA) intended for lymphoma treatment.

Esperion Therapeutics (ESPR) reached a significant milestone with FDA approval expanding labels for NEXLETOL and NEXLIZET, enabling heart attack prevention irrespective of statin usage, underscoring ESPR's steadfast commitment to cardiovascular health.

VANDA PHARMACEUTICALS (VNDA) celebrated FDA approval for the extended use of Fanapt in treating bipolar I disorder, demonstrating VNDA's dedication to addressing mental health needs and broadening treatment alternatives.

Announcing Today

Legend Biotech Corporation (LEGN) eagerly anticipates the FDA's decision on Carvykti's supplemental Biologics License Application (sBLA). The company aims to expand Carvykti's usage to include earlier treatment for patients with relapsed or refractory multiple myeloma, potentially transforming the treatment paradigm for this challenging disease.

Johnson & Johnson (JNJ) stands on the brink of a significant milestone as it awaits the FDA's decision on Carvykti's expanded usage. The company seeks approval for treating adult patients with relapsed or refractory multiple myeloma who have undergone at least one prior line of therapy. This decision holds the promise of providing a new therapeutic option for patients facing limited treatment options.

Supernus Pharmaceuticals, Inc. (SUPN) is poised for a potential breakthrough with the pending FDA decision on SPN-830. This drug targets the continuous treatment of motor fluctuations in Parkinson’s disease, addressing a significant unmet need in Parkinson’s treatment. If approved, SPN-830 could offer patients a novel therapeutic approach to managing the challenging symptoms of this neurodegenerative disorder.

Upcoming Announcements

With April 23, 2024, marked on the calendar, ImmunityBio, Inc. (IBRX) holds its breath, awaiting the FDA's verdict on N-803 plus BCG for high-risk non-muscle-invasive bladder cancer. The resubmitted Biologics License Application (BLA) represents a beacon of hope for patients grappling with this formidable disease, potentially heralding a new era in treatment options.

As April 28, 2024, approaches, Aquestive Therapeutics Inc. (AQST) braces for a pivotal moment in its journey. The FDA's impending decision on Libervant, designed to tackle seizure clusters in children aged two to five with its diazepam buccal film, carries profound implications. Should approval be granted, it could offer solace to families navigating the challenges of pediatric epilepsy.

With April 30, 2024, looming on the horizon, Neurocrine Biosciences Inc. (NBIX) finds itself on the cusp of a breakthrough. The FDA's looming decision on INGREZZA oral granules promises a potential game-changer in the treatment landscape for tardive dyskinesia. This innovative formulation could provide patients with newfound hope and healthcare providers with a more convenient option for managing this complex neurological disorder.

Happy investing,

Maeve Grace
Editor In Cheif
Premium Trade Alerts

Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.